Printer Friendly

China Medical Technologies and the Chinese Academy of Sciences Institute of Acoustics Establish a Medical Research Laboratory to Develop Acoustic Medical Devices.

BEIJING -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that the Company has entered into a 10-year collaboration agreement with the Chinese Academy of Sciences Institute of Acoustics (the "Institute") to establish a medical research laboratory that is expected to be used as a platform for the development and commercialization of acoustic medical devices. The goal of this initiative is to enhance the Company's research capabilities, expedite the development of new products as well as to expand the Company's product range.

Under the terms of the agreement, China Medical will be responsible for all of the development costs and will in turn retain the intellectual property rights relating to these products. The Company expects to fund the laboratory on a project basis over the 10-year period. The potential and feasibility of each project will be thoroughly and cautiously assessed by the Company together with the Institute. The related budget of each project will be examined prior to entering into any capital commitments.

As a well-established research institution in China, the Institute has been engaged in a vast number of national research projects in acoustic and signal information analysis, and ultrasonic and linguistic acoustics since its founding in 1964. Its key achievements include over 400 established research results and over 300 national winning awards on the related subjects. This collaboration is expected to also help strengthen the Institute's position in academic and clinical studies.

"We believe that this synergistic collaboration is an excellent strategy for the Company and underscores our commitment to broaden the scope of our acoustic and ultrasound technologies," said Mr. Xiaodong Wu, Chairman and CEO. "We are encouraged by the many mutual benefits that this collaboration provides and believe that acoustic medical products have great potential to further improve the quality of human lives. Overall, we think this is a great opportunity for us to broaden and diversify our product offering in the medical device market in China while remaining firmly in an area that we know well, with partners we trust. We are now actively assessing the potential of a number of acoustic projects with the Institute, and we will continue to search for other opportunities in the market that will allow us to follow through on our stated goal of becoming the leading medical device company in China."

Leveraging the existing acoustic technology and expertise of the Institute, China Medical aims to develop affordable acoustic medical devices that address the needs of patients, and the vast and untapped market potential that exists in China. The Company believes that its proven track record of developing high quality medical devices, strong distribution network, and well established commitment to controlling costs will allow the Company to benefit from the research and development of these innovations. The Company looks forward to disclosing specific product development plans once a thorough assessment has been completed.

About China Medical Technologies

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets products using high intensity focused ultrasound for the treatment of solid cancers and benign tumors and advanced in-vitro diagnostics products using enhanced chemiluminescence technology, to detect and monitor various diseases and disorders. For more information, please visit our website at www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the Company's expectation and strategy with respect to researching and developing the above mentioned acoustic medical devices with collaboration of the Institute contains forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in China Medical's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. China Medical does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 6, 2006
Words:738
Previous Article:RFI closes Industrial Minerals Corp Ltd Transaction Facilitating Next Stage Funding for Oregon Resources Corp Through ASX Listing.
Next Article:Arcelor Mittal Announces Re-Organisation of Senior Management Structure Mr Lakshmi N. Mittal to Become CEO.
Topics:


Related Articles
Chinese test-tube baby born.
Where are we headed? Experts to review state of MS knowledge.
Vulimiri Ramalingaswami (1921-2001).
CapitalBio and Affymetrix to Support and Promote Rice Functional Genomic Research in China.
Kikusui Electronics Partners with Dalian Institute of Chemical Physics to Develop Fuel Cell Evaluation Technologies.
AIST Introduces Portable Ultrasound Which Measures Muscles, Bones, and Subcutaneous Fat.
Pivotal role of dogs in rabies transmission, China.
Takara Bio Chinese Subsidiary to Expand Lines of Business, Files Chinese Clinical Trial Application.
Correction.
Bio-Bridge Science Signs Cooperative Agreement with Chinese Academy of Medical Sciences for Vaccine Development.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters